Clinical Trial Update: Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated whether pyridoxine and a topical urea/lactic acid-based cream can prevent hand-foot syndrome in patients treated with capecitabine for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyridoxine (Pyridoxine)
• Topical urea/lactic acid-based cream (urea/lactic acid-based cream)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ | Phase 3 | Status: COMPLETED | Results posted: 2017-03-16